Atlantic Healthcare Completes Phase 3 Trial Enrollment for Alicaforsen as Pouchitis Treatment

Atlantic Healthcare Completes Phase 3 Trial Enrollment for Alicaforsen as Pouchitis Treatment
Atlantic Healthcare has completed enrollment for a Phase 3 trial evaluating the safety and efficacy of alicaforsen in patients with pouchitis, a frequent complication after surgery to treat different forms of inflammatory bowel disease (IBD). IBD patients have increased production of ICAM-1 protein, which correlates with intestinal inflammation. Alicaforsen binds specifically to the human ICAM-1

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *